research Alopecia areata presenting in 2 kidney-pancreas transplant recipients taking cyclosporine
Two transplant patients on cyclosporine unexpectedly developed hair loss.
Search
for
Sort by
Research
510-540 / 1000+ results research Alopecia areata: A clinical review of the changing landscape with Janus kinase inhibitors
Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.
research Reduced Prostate Cancer Risk in Patients with Androgenetic Alopecia Using 5-Alpha Reductase Inhibitors: A TriNetX Real-World Cohort Study
Using 5-alpha reductase inhibitors may lower prostate cancer risk in people with androgenetic alopecia.
research 5-Alpha Reductase Inhibitors in Prostate Cancer: From Clinical Trials to Clinical Practice
5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.
research Finasteride reduces the preventive effect of uroselective α1A-blockers against cancellous bone disorders induced by androgen deficiency in rats
Finasteride weakens the bone-protective effects of certain blockers in low androgen conditions.
research Interventions for preventing the progression of autosomal dominant polycystic kidney disease
Tolvaptan can slow kidney disease progression, but doesn't affect mortality or kidney failure.
research Design, synthesis and biological evaluation of novel 3-oxo-4-oxa-5α-androst-17β-amide derivatives as dual 5α-reductase inhibitors and androgen receptor antagonists
New compounds were made that are promising for prostate cancer therapy.
research Exploring novel management options for alopecia areata
JAK inhibitors can help treat alopecia areata but have risks and high costs.
research Avicequinone C Isolated from Avicennia marina Exhibits 5α-Reductase-Type 1 Inhibitory Activity Using an Androgenic Alopecia Relevant Cell-Based Assay System
Avicequinone C, a compound found in the Avicennia marina plant, can reduce hair loss by inhibiting a hormone linked to androgenic alopecia.
research Antiviral drugs prolong survival in murine recessive dystrophic epidermolysis bullosa
Antiviral drugs, especially daclatasvir, may be a new treatment for a rare skin disease, improving survival and reducing symptoms in mice.
research Adverse events associated with aromatase inhibitors: an analysis of real-world datasets and drug-gene interaction network
research 5-alpha reductase inhibitors use in prostatic disease and beyond
5-alpha reductase inhibitors, like finasteride and dutasteride, are used for prostate issues, hair loss, and excessive hair growth, may help with COVID-19, but can cause sexual and mental health side effects, and their use in preventing prostate cancer needs more examination.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research Real‐life effectiveness and safety of baricitinib in adults with alopecia areata: A multicentre study
Baricitinib effectively reduces hair loss in alopecia areata and is well-tolerated.
research The efficacy and particular side effects of therapy peginterferon alpha-2a acute hepatitis C hemodialysed patients
Peginterferon alpha-2a effectively treats acute hepatitis C in hemodialysed patients, despite some side effects.
research 975 Antifibrogenic activities of novel vitamin D3 analogs are dependent on VDR expression in human fibroblasts
New vitamin D3 forms need the vitamin D receptor to reduce fibrosis in human cells.
research TGF-β Signaling: a Potential Therapeutic Target of Single Herbs and Extracts for Renal Fibrosis
Certain Chinese herbs may help treat kidney fibrosis by targeting TGF-β.
research Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.
research THE ROLE Of 5αR AND α1AR INHIBITORS IN MANAGEMENT OF BPH
Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
research Design, synthesis and biological evaluation of novel androst-3,5-diene-3-carboxylic acid derivatives as inhibitors of 5α-reductase type 1 and 2
New chemical compounds were made that effectively block an enzyme linked to prostate growth.
research Mineralocorticoid Receptor Antagonists—A New Sprinkle of Salt and Youth
MR antagonists may improve skin health and wound healing, especially in aging.
research 5‐alpha‐reductase inhibitors are associated with reduced frequency of COVID‐19 symptoms in males with androgenetic alopecia
5-alpha-reductase inhibitors may reduce COVID-19 symptoms in bald males.
research AKR1D1 regulates glucocorticoid availability and glucocorticoid receptor activation in human hepatoma cells
AKR1D1 controls glucocorticoid levels and receptor activity in liver cells.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research Adverse Effects of 5-Alpha-Reductase Inhibitors: a narrative review
5-Alpha-Reductase Inhibitors can cause negative side effects.
research CUTANEOUS SIDE-EFFECTS OF BETA-ADRENERGIC BLOCKERS
Beta-blockers can cause rare skin side-effects, which usually improve after stopping the medication.
research Baricitinib: A Review in Severe Alopecia Areata
Baricitinib helps regrow hair in severe alopecia areata but has side effects like infections and headaches.
research Medication Clusters at Hospital Discharge and Risk of Adverse Drug Events at 30-days Post-Discharge: A Population-based Cohort Study of Older Adults
Certain groups of medications given when leaving the hospital are linked to a higher risk of negative drug reactions within 30 days, especially in older adults with respiratory issues.
research A cross‐sectional analysis of medications used by patients reporting alopecia areata on the FDA adverse events reporting system
Monoclonal antibodies are often linked to alopecia areata cases.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
PDE5 inhibitors cause earlier adverse events in BPH treatment, requiring careful monitoring.